Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences
Last week, Ocular Therapeutix Inc.
Ocular Therapeutix Inc (OCUL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 11,932,137 | $139,486,682 | -17% | 3.89% |
| 2. | VenBio Select Advisor Kurt Von Emster | 10,250,000 | $119,822,500 | +39% | 1.55% |
| 3. | Citadel Investment Group Ken Griffin | 5,703,781 | $66,677,200 | +17% | 0.01% |
| 4. | Point72 Asset Management Steve Cohen | 4,601,321 | $53,789,442 | +142% | 0.09% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 4,004,350 | $46,810,852 | +3% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.96 | 10,000 | $69,600.00 | 172,704 | 2025-05-08 | Filing | |
| $7.52 | 930,851 | $6,999,999.52 | 8,591,401 | 2024-02-26 | Filing | |
| $3.25 | 1,538,461 | $4,999,998.25 | 7,660,550 | 2023-12-14 | Filing | |
| $3.81 | 6,500 | $24,765.00 | 6,500 | 2023-08-30 | Filing | |
| $3.50 | 7,328 | $25,648.00 | 6,122,089 | 2022-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.04 | 1,878 | $22,611.12 | 277,860 | 2025-11-24 | Filing | |
| $12.04 | 19,530 | $235,141.20 | 3,157,960 | 2025-11-24 | Filing | |
| $12.02 | 3,007 | $36,144.14 | 191,433 | 2025-11-24 | Filing | |
| $12.04 | 3,469 | $41,766.76 | 245,940 | 2025-11-24 | Filing | |
| $10.74 | 25,865 | $277,790.10 | 174,135 | 2025-11-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 31,785,634 | $371,574,056 | 0.02% | |
| 2. | 13,161,462 | $153,857,491 | 8.66% | |
| 3. | 12,579,657 | $147,050,970 | 98.57% | |
| 4. | 10,556,837 | $123,409,426 | 0% | |
| 5. | 9,163,240 | $107,118,275 | 0% |
News See All
RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory
The revised target was attributed to the company’s strong execution in its SOL-1 wet age-related macular degeneration (wAMD) superiority study.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Ocular Therapeutix Third Quarter 2025 Earnings Conference Call.
H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best healthcare stocks with the highest upside. Ocular Therapeutix Inc. (NASDAQ:OCUL) received a rating update from H.C. Wainwright on October 8.
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks with high potential. On October 3, Piper Sandler raised the firm’s price target on Ocular Therapeutix Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale
In a statement, Ocular Therapeutix Inc.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
Hedge Fund Resource Center Billionaire Hedge Funds
